readthroughSign in
Jul 16, 2026Partnership

Calidi Biotherapeutics signs new San Diego lease, ends current one early

The company will move to a new office and lab space in October 2026 and expects to save about $1.1 million a year in rent and facility costs.

Calidi Biotherapeutics, Inc. disclosed in an 8-K that on July 10, 2026 it entered into a lease agreement with BP3-SD4 5580 Morehouse Drive LLC to lease approximately 9,038 rentable square feet of office and laboratory space in Suite 120 at 5580 Morehouse Drive, San Diego, California.1 The new landlord is an affiliate of 4475 Executive Drive LLC, the landlord under Calidi's existing lease.1

Calidi said it expects to save approximately $1.1 million per year in rent and facility-related expenses by terminating the existing lease and entering into the new one.1 The new lease has an initial term of 44 months, set to begin October 1, 2026 and end May 31, 2030.1 Calidi has one option to extend the term for an additional three years at the then-prevailing market rate, provided it has not defaulted and occupies at least 50% of the space at the time of exercise.1

Within 10 days of signing, Calidi must deliver an irrevocable letter of credit for $113,574.78, which must generally stay in effect until at least 120 days after the lease expires.1

Separately, Calidi and 4475 Executive Drive LLC signed a termination agreement covering the prior lease dated October 10, 2022 for space on the second floor of 4475 Executive Drive, which had been set to expire in February 2027.1 That prior lease will now terminate effective September 30, 2026.1 If the new space is not ready by then, Calidi may stay in the current space up to 14 additional days, with the termination date shifting to when it actually vacates.1 No early termination fee applies under the agreement.1

The filing does not disclose the square footage of the existing premises, so no size comparison between the two spaces can be made from the available information.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.